8 research outputs found

    Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Get PDF
    Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

    Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Get PDF
    Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

    IEP

    No full text
    TĂ­tulo tomado de la pĂĄgina de inicio. Visitado el 19 de abril de 2011Title from title from title screen (viewed Apr. 19, 2011).Sumario: "The Internet Encyclopedia of Philosophy was founded in 1995 for the purpose of providing detailed, scholarly information on key topics and philosophers in all areas of philosophy." Articles are currently from three sources: (1) original contributions by specialized philosophers around the Internet; (2) adaptations of material written by the editors for classroom purposes; and (3) adaptations from public domain sources (typically from two or more sources for per article). The IEP offers access to a keyword site search engine and is free of charge to all Internet users. It is continuously revised and updated.Sumario: La Internet Encyclopedia of Philosophy se creĂł en 1995 con el fin de proporcionar informaciĂłn acadĂ©mica mĂĄs detallada sobre temas clave y filĂłsofos en todos los ĂĄmbitos de la filosofĂ­a. Los artĂ­culos son en la actualidad de tres fuentes: (1) las contribuciones originales de filĂłsofos especializados en torno a Internet, (2) adaptaciones de material escrito por los editores para sus clases, y (3) adaptaciones de fuentes de dominio pĂșblico (por lo general a partir de dos o mĂĄs fuentes por artĂ­culo). El IEP ofrece acceso a un motor de bĂșsqueda de palabras clave del sitio y es gratis para todos los usuarios de Internet. Se actualiza y modifica constantemente.Mode of access: World Wide Web.Modo de acceso: World Wide Web

    IEP

    No full text
    TĂ­tulo tomado de la pĂĄgina de inicio. Visitado el 19 de abril de 2011Title from title from title screen (viewed Apr. 19, 2011).Sumario: "The Internet Encyclopedia of Philosophy was founded in 1995 for the purpose of providing detailed, scholarly information on key topics and philosophers in all areas of philosophy." Articles are currently from three sources: (1) original contributions by specialized philosophers around the Internet; (2) adaptations of material written by the editors for classroom purposes; and (3) adaptations from public domain sources (typically from two or more sources for per article). The IEP offers access to a keyword site search engine and is free of charge to all Internet users. It is continuously revised and updated.Sumario: La Internet Encyclopedia of Philosophy se creĂł en 1995 con el fin de proporcionar informaciĂłn acadĂ©mica mĂĄs detallada sobre temas clave y filĂłsofos en todos los ĂĄmbitos de la filosofĂ­a. Los artĂ­culos son en la actualidad de tres fuentes: (1) las contribuciones originales de filĂłsofos especializados en torno a Internet, (2) adaptaciones de material escrito por los editores para sus clases, y (3) adaptaciones de fuentes de dominio pĂșblico (por lo general a partir de dos o mĂĄs fuentes por artĂ­culo). El IEP ofrece acceso a un motor de bĂșsqueda de palabras clave del sitio y es gratis para todos los usuarios de Internet. Se actualiza y modifica constantemente.Mode of access: World Wide Web.Modo de acceso: World Wide Web

    Thigh-length compression stockings and DVT after stroke

    Get PDF
    Controversy exists as to whether neoadjuvant chemotherapy improves survival in patients with invasive bladder cancer, despite randomised controlled trials of more than 3000 patients. We undertook a systematic review and meta-analysis to assess the effect of such treatment on survival in patients with this disease

    Did Magic Matter? The Saliency of Magic in the Early Roman Empire

    No full text

    Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Get PDF
    Background Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19. Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospital with COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients were randomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once per day by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatment groups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment and were twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants and local study staff were not masked to the allocated treatment, but all others involved in the trial were masked to the outcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) were eligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was 65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomly allocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall, 561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days (rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median 10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days (rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, no significant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilation or death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24). Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or other prespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restricted to patients in whom there is a clear antimicrobial indication. Funding UK Research and Innovation (Medical Research Council) and National Institute of Health Research

    References

    No full text
    corecore